



## Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

July 7, 2021

BOSTON--(BUSINESS WIRE)--Jul. 7, 2021-- [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13<sup>th</sup>, 2021 at 12:30pm ET.

A webcast of the presentation will be available at the following link: <https://wsw.com/webcast/ladenburg7/catb/2378558>, and will also be available in the investors section of the Company's website, [www.catabasis.com](http://www.catabasis.com), and will be archived for 30 days following the presentation.

### About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20210707005084/en/>

Catabasis:

**Investor relations:**

Andrea Matthews

[investors@catabasis.com](mailto:investors@catabasis.com)

**Media:**

Elizabeth Higgins

[media@catabasis.com](mailto:media@catabasis.com)

Source: Catabasis Pharmaceuticals, Inc.